TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.
Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.
Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.
We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.
Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.
Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.
We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.
Location: France
Employees: 51-200
Total raised: $233.3M
Founded date: 2013
Investors 8
Funding Rounds 5
| Date | Series | Amount | Investors |
| 05.07.2026 | - | $68.62M | European I... |
| 23.05.2023 | Series D | $54.11M | - |
| 01.09.2021 | Series C | $59.17M | - |
| 01.10.2020 | - | $8.2M | - |
| 26.11.2019 | Series B | $43.2M | - |
Mentions in press and media 27
| Date | Title | Description |
| 05.07.2026 | TISSIUM Secures €60 Million Financing Package To Support Commercial And Clinical Activities | TISSIUM announced a €60 million financing package to support its commercial and clinical activities and platform expansion. The package combines a completed €30 million Series D2 financing with a €30 million financing facility from the Euro... |
| 30.06.2026 | TISSIUM Secures €60 Million, Accelerates U.S. Market Entry with Innovative Biomorphic Polymers | TISSIUM secures €60 million in crucial financing. This capital propels global commercial and clinical expansion. The MedTech innovator launches its FDA-approved COAPTIUM CONNECT in the vital U.S. market. It champions a breakthrough biomorph... |
| 30.06.2026 | Tissium Raises €60M in Equity and Debt Financing | Tissium, a Paris, France-based developer of biomorphic programmable polymers for tissue reconstruction, secured a €60m (approximately $64m) financing package. The transaction comprised: a €30m Series D2 equity round backed by international ... |
| 29.06.2026 | European tech weekly recap: €2.1B in deals and Tech.eu Funding Explorer | Last week, we tracked more than 75 tech funding deals worth over €2.1 million and over 5 exits, M&A transactions, rumours, and related news stories across Europe. 📊 The top three industries that raised the most were fintech (€502.9 mill... |
| 25.06.2026 | TISSIUM Secures €60 Million To Support Commercial And Clinical Expansion | TISSIUM announced a €60 million financing package to support its commercial and clinical activities, pipeline development, and platform expansion. The financing package includes a completed €30 million Series D2 financing and a financing fa... |
| 24.06.2026 | Tissium raises €30M in equity funding, €30M in debt | A French startup which uses a novel technology to reconstruct damaged tissue and restore it to its natural state has raised €30m in equity funding and taken out up to €30m in debt financing, it said today. Tissium has developed materials ca... |
| 17.12.2025 | 3D Systems Secures FDA Clearance to Broaden Adolescent Use of VSP Orthopedics Platform | US-based 3D printer manufacturer 3D Systems has received U.S. Food and Drug Administration 510(k) clearance broadening the approved use of its VSP Orthopedics virtual surgical planning and patient-specific instrumentation platform. The clea... |
| 01.09.2025 | Tissium receives FDA authorization for suture-free nerve repair system | Tissium, a Paris-based medical technology company founded on MIT research, has secured De Novo marketing authorization from the U.S. Food and Drug Administration for its non-traumatic peripheral nerve repair platform. The clearance enables ... |
| 30.06.2025 | 3D Systems and TISSIUM Receive FDA Approval for First-of-its-Kind Peripheral Nerve Repair Device | U.S.-based 3D printer manufacturer 3D Systems, in partnership with French MedTech firm TISSIUM, has secured FDA approval for a bioabsorbable, 3D printed device designed to treat peripheral nerve damage. This approval validates the polymer’s... |
| 27.06.2025 | FDA clears path for Paris startup TISSIUM's tissue reconstruction without sutures, redefining surgical standards | Nerve injuries affect hundreds of thousands of patients each year. Typically, they’re repaired using microsurgical stitches. However, the process is technically complex, with a risk of additional trauma to surrounding tissues and long perio... |
Show more